Syngen Biotech Statistics

Total Valuation

Syngen Biotech has a market cap or net worth of TWD 3.85 billion. The enterprise value is 3.81 billion.

Market Cap	3.85B
Enterprise Value	3.81B

Important Dates

The last earnings date was Tuesday, May 13, 2025.

Earnings Date	May 13, 2025
Ex-Dividend Date	Jun 27, 2024

Share Statistics

Syngen Biotech has 27.10 million shares outstanding. The number of shares has decreased by -0.13% in one year.

Current Share Class	27.10M
Shares Outstanding	27.10M
Shares Change (YoY)	-0.13%
Shares Change (QoQ)	-0.30%
Owned by Insiders (%)	8.15%
Owned by Institutions (%)	4.29%
Float	10.54M

Valuation Ratios

The trailing PE ratio is 15.94.

PE Ratio	15.94
Forward PE	n/a
PS Ratio	1.89
PB Ratio	1.78
P/TBV Ratio	1.80
P/FCF Ratio	12.39
P/OCF Ratio	10.45
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.14, with an EV/FCF ratio of 12.28.

EV / Earnings	15.78
EV / Sales	1.88
EV / EBITDA	9.14
EV / EBIT	12.79
EV / FCF	12.28

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.13.

Current Ratio	1.63
Quick Ratio	1.07
Debt / Equity	0.13
Debt / EBITDA	0.67
Debt / FCF	0.90
Interest Coverage	35.60

Financial Efficiency

Return on equity (ROE) is 11.46% and return on invested capital (ROIC) is 7.48%.

Return on Equity (ROE)	11.46%
Return on Assets (ROA)	6.02%
Return on Invested Capital (ROIC)	7.48%
Return on Capital Employed (ROCE)	12.67%
Revenue Per Employee	8.23M
Profits Per Employee	978,126
Employee Count	247
Asset Turnover	0.65
Inventory Turnover	3.70

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.39% in the last 52 weeks. The beta is 0.11, so Syngen Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.11
52-Week Price Change	-8.39%
50-Day Moving Average	124.74
200-Day Moving Average	132.04
Relative Strength Index (RSI)	76.00
Average Volume (20 Days)	27,044

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Syngen Biotech had revenue of TWD 2.03 billion and earned 241.60 million in profits. Earnings per share was 8.91.

Revenue	2.03B
Gross Profit	732.92M
Operating Income	300.43M
Pretax Income	304.47M
Net Income	241.60M
EBITDA	403.52M
EBIT	300.43M
Earnings Per Share (EPS)	8.91

Full Income Statement

Balance Sheet

The company has 316.91 million in cash and 280.58 million in debt, giving a net cash position of 36.33 million or 1.34 per share.

Cash & Cash Equivalents	316.91M
Total Debt	280.58M
Net Cash	36.33M
Net Cash Per Share	1.34
Equity (Book Value)	2.16B
Book Value Per Share	79.91
Working Capital	439.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 368.23 million and capital expenditures -57.74 million, giving a free cash flow of 310.49 million.

Operating Cash Flow	368.23M
Capital Expenditures	-57.74M
Free Cash Flow	310.49M
FCF Per Share	11.46

Full Cash Flow Statement

Margins

Gross margin is 36.07%, with operating and profit margins of 14.79% and 11.89%.

Gross Margin	36.07%
Operating Margin	14.79%
Pretax Margin	14.98%
Profit Margin	11.89%
EBITDA Margin	19.86%
EBIT Margin	14.79%
FCF Margin	15.28%

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 3.69%.

Dividend Per Share	5.00
Dividend Yield	3.69%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	56.09%
Buyback Yield	0.13%
Shareholder Yield	3.82%
Earnings Yield	6.28%
FCF Yield	8.07%

Dividend Details

Stock Splits

The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.

Last Split Date	Jul 9, 2018
Split Type	Forward
Split Ratio	1.1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a